TKEG Expat ™ (HK SAR)
Medical Device License in China: Complete Guide to NMPA Registration and Approval (2022)

Medical Device License in China: Complete Guide to NMPA Registration and Approval (2022)

Also available in:

Trading or manufacturing medium- and high-risk medical devices in China requires a license issued by the National Medical Products Administration (NMPA). Whether you are a domestic manufacturer or a foreign company looking to enter the Chinese market, understanding the classification system, registration pathway, and regulatory requirements is essential. This guide covers every aspect of the medical device licensing process in China as of 2026.

The Three Classes of Medical Devices

China classifies medical devices into three categories based on risk level. The classification determines which authority handles registration and the complexity of the approval process.

ClassRisk LevelExamples
Class ILow riskBasic instruments such as surgical dressings, tongue depressors, manual surgical tools, and simple diagnostic aids
Class IIMedium riskBlood pressure monitors, pregnancy test kits, powered surgical instruments, clinical thermometers, dental materials
Class IIIHigh riskImplantable devices, life-support equipment, coronary stents, artificial joints, pacemakers

The higher the class, the more rigorous the pre-market evaluation. Class I devices only require a record filing, while Class II and Class III devices must undergo formal registration and review.

Pre-Market Approval: The NMPA Registration Requirement

All medical devices sold or used in China must complete pre-market product registration with NMPA. The process differs significantly depending on whether the product is manufactured domestically or imported from abroad. There are three levels of regulatory management: the national-level NMPA, provincial-level medical products bureaus, and municipal-level bureaus.

Registration for Imported Medical Devices

Foreign manufacturers must register their devices through the national NMPA. In all cases, a local authorized representative in China must serve as the Marketing Authorization Holder (MAH).

Device ClassRegistration RequirementLicense Requirement
Class IIINMPA registration certificateNMPA MAH license
Class IINMPA registration certificateNMPA MAH license
Class INMPA record filingNMPA MAH license
Key point for foreign manufacturers: A local Chinese representative is mandatory. This representative acts as the MAH and takes regulatory responsibility for the imported device within China. The representative must be a legally registered entity in China with the ability to handle post-market obligations including adverse event reporting and recalls.

Registration for Domestic Medical Devices

Domestic manufacturers register through different government levels depending on device classification.

Device ClassRegistration RequirementProduction Requirement
Class IIINMPA registrationProvincial production license
Class IIProvincial registrationProvincial production license
Class IMunicipal record filingMunicipal production record

Step-by-Step: Imported Medical Device Registration Process

The registration process for imported medical devices is detailed and can take two or more years from start to finish. Below is the complete workflow.

Step 1: Determine Device Classification and Plan Strategy

Begin by confirming which class your device falls under according to the NMPA classification catalogue. This determines the regulatory pathway, documentation requirements, and estimated timeline. Plan your strategy around clinical trial requirements, standards compliance, and the appointment of a local authorized representative.

Step 2: Ensure Compliance with Applicable Standards

Products must meet all relevant national standards (GB), industrial standards (YY), and applicable international standards (ISO/IEC). These cover performance specifications, safety requirements, and inspection methodologies. Verify compliance early, as gaps discovered later will cause significant delays.

Step 3: Type Inspection (Prototype Testing)

Once a production-ready prototype is available, submit it for type inspection at an NMPA-recognized testing institution. This inspection verifies that the device meets all declared standards and specifications. The type inspection process typically takes a minimum of six months, though timelines vary based on device complexity and testing institution workload.

Step 4: Clinical Trials

After receiving the type inspection report, most devices require clinical trials conducted at NMPA-approved clinical trial institutions in China. Clinical trials typically take one year or longer, depending on the device and indication.

Clinical trial exemptions: NMPA maintains a catalogue of devices exempt from clinical trials. If your device falls within this catalogue, you may substitute clinical data with a comparison report against similar products already marketed in China. This can save significant time and cost. Check the current exemption catalogue before planning your clinical strategy.

Step 5: Prepare Regulatory Documentation

Regulatory document preparation should run concurrently with type inspection and clinical trials. The documentation package includes risk management reports, product technical requirements, quality management system documentation, clinical evaluation reports, and all supporting evidence for safety and efficacy claims.

Step 6: Submit Registration Application and Review

The final step is submission to the Center for Medical Device Evaluation (CMDE). The review proceeds as follows:

First review: CMDE conducts an initial technical review within 60 to 90 working days.

Corrective notice: If deficiencies are identified, the applicant receives a corrective notice. All corrections must be submitted within one year of the notice date; failure to respond within this window results in automatic rejection.

Second review: For Class II and Class III devices, a second round of technical review is conducted after corrections are submitted.

Administrative approval: Once technical review is complete, the administrative approval decision is issued within approximately 20 working days.

Fast-Track Approval Pathways

NMPA offers two accelerated review channels for qualifying devices. These pathways can significantly reduce the time to market.

Innovative Medical Device Review

This pathway is designed for genuinely novel devices. To qualify, the device must meet all of the following criteria:

  • The applicant holds a core technology patent for the device
  • The device is the first of its kind in China
  • The device demonstrates significant clinical value over existing alternatives
Benefits of the innovative device pathway: Pre-registration consultancy with NMPA reviewers, assignment of a dedicated reviewer for the application, and priority scheduling during the review process.

Medical Device Priority Approval

This pathway covers devices that address unmet clinical needs. Eligible categories include:

  • Devices urgently needed in clinical practice
  • Devices developed under state key research and development projects
  • Devices targeting rare diseases that offer obvious advantages over current options
  • Pediatric-specific devices
  • Devices for elderly disease management where no current alternatives exist
Benefits of the priority approval pathway: Access to special communication channels with NMPA, and priority scheduling for technical review and administrative approval.

Documentation Requirements for Registration

The registration dossier for medical devices in China is comprehensive. Below is an overview of the key documents required.

CategoryRequired Documents
Applicant InformationApplicant identification documents, business license, authorized representative credentials (for foreign applicants)
Intellectual PropertyIP identification and ownership documentation, patent certificates, IP analysis report
Technical DocumentationR&D summary report, intended use description, working principle explanation, raw material specifications, manufacturing process documentation
Clinical and SafetyClinical value literature review, similar product comparison analysis, safety and risk management report, innovation analysis
Product InformationProduct operation manual, labeling, packaging specifications
Foreign applicants: All foreign manufacturers must appoint an Authorized Representative in China. The representative is responsible for regulatory submissions, communications with NMPA, post-market surveillance, and adverse event reporting on behalf of the overseas manufacturer.

Timeline Summary

The total timeline for imported medical device registration varies widely based on device class, clinical trial requirements, and review cycles. The following estimates represent typical durations.

PhaseEstimated Duration
Classification and strategy planning1 to 2 months
Standards compliance verification2 to 4 months
Type inspection (prototype testing)6 months minimum
Clinical trials (if required)12 months or more
CMDE first review60 to 90 working days
Corrections and second reviewVariable (up to 12 months for corrections)
Administrative approvalApproximately 20 working days

For devices exempt from clinical trials, the total process may take 18 to 24 months. For devices requiring clinical trials, expect 2 to 4 years from initial planning to approval.

Related Articles

NVOCC License in China: Complete Guide 2022
Chinese Mainland

NVOCC License in China: Complete Guide 2022

See how to register an NVOCC license in China, including carrier categories, MOT filing, freight rate records, required documents, and liaison duties.

Learn More >
Import & Export Certificate in China: Complete Guide 2022
Chinese Mainland

Import & Export Certificate in China: Complete Guide 2022

Learn how China import and export certificates affect customs clearance, including export licenses, import controls, automatic licensing, and e-Port registration.

Learn More >
ICP License in China: Everything You Need to Know in 2022
Chinese Mainland

ICP License in China: Everything You Need to Know in 2022

Understand China ICP filing and commercial ICP licenses for websites and e-commerce, including MIIT steps, foreign ownership limits, timelines, and hosting risks.

Learn More >
Food Licenses in China: Production, Catering & Distribution (2022 Guide)
Chinese Mainland

Food Licenses in China: Production, Catering & Distribution (2022 Guide)

Learn which China food license a business needs for production, catering, or distribution, with regulators, application materials, inspections, and renewal timing.

Learn More >
Alcohol & Liquor License in China 2022: Complete Guide
Chinese Mainland

Alcohol & Liquor License in China 2022: Complete Guide

Understand China alcohol licensing for import, wholesale, and retail sales, including capital thresholds, premises rules, authorities, renewal cycles, and documents.

Learn More >
CIT Reduction for Encouraged Software IC Design Enterprises
Chinese Mainland

CIT Reduction for Encouraged Software IC Design Enterprises

China offers a five-year CIT exemption and 10% reduced rate for qualified encouraged software and IC design enterprises. Review criteria for revenue, R&D and IP.

Learn More >
CIT Reduction for Lingang New Are (Airport-Economic-Area) of Shanghai
Chinese Mainland

CIT Reduction for Lingang New Are (Airport-Economic-Area) of Shanghai

Qualified companies in Shanghai Lingang New Area can access a 15% CIT rate for key production or R&D in IC, AI, biomedicine and civil aviation fields.

Learn More >
CIT Reduction for Pingtan Comprehensive Experimental Zone
Chinese Mainland

CIT Reduction for Pingtan Comprehensive Experimental Zone

Enterprises in the Pingtan Comprehensive Experimental Zone may qualify for a 15% CIT rate across high-tech, logistics, tourism, marine and service industries.

Learn More >
CIT Reduction in Qianhai Shenzhen-Hong Kong Modern Services Industry Cooperation Zone
Chinese Mainland

CIT Reduction in Qianhai Shenzhen-Hong Kong Modern Services Industry Cooperation Zone

Companies in Qianhai Shenzhen-Hong Kong Modern Services Cooperation Zone may qualify for a 15% CIT rate when catalogued modern service income exceeds 60%.

Learn More >
CIT Reduction for Qualified High New Technology Enterprises in China
Chinese Mainland

CIT Reduction for Qualified High New Technology Enterprises in China

Qualified High and New Technology Enterprises in China can reduce CIT from 25% to 15%. Learn the HNTE criteria for industries, R&D spend, IP and revenue.

Learn More >
CIT Reduction for Technology Advanced Enterprises in China
Chinese Mainland

CIT Reduction for Technology Advanced Enterprises in China

Technologically advanced service enterprises in China may qualify for 15% CIT and staff education deductions. Check outsourcing, revenue and filing rules.

Learn More >
Qualified Foreign-Invested Businesses in Chinese Western and Central Provinces Enjoy a Reduced CIT Rate of 15%
Chinese Mainland

Qualified Foreign-Invested Businesses in Chinese Western and Central Provinces Enjoy a Reduced CIT Rate of 15%

Qualified foreign-invested companies in central and western China may access a 15% CIT rate. Learn covered provinces, encouraged industries, and tax benefits.

Learn More >

A Full-Service Consulting Firm Backs You Up

TKEG Expat is your trusted overseas business partner. We are the retail consulting department of THE KEITH &EVEN GROUP, a Hong Kong-based global consulting agency with access to 50 markets, covering approximately 72 percent of global GDP.
With its strategic advantages, we can connect customers to opportunities worldwide and serve them in 21 industries.

Learn More About THE KEITH & EVEN GROUP >
A Full-Service Consulting Firm Backs You Up
Corporate Clients Overseas Expansion
Corporate Clients

Do You Represent A Big Corporation Or Already Have 10 Million USD In Revenue?

If you represent a big corporation, or if your company already has more than $10 million USD in revenue, you may be interested in the enterprise solutions provided by THE KEITH &EVEN GROUP.

Enterprise Solutions >
TKEG Expat ™ (HK SAR) provides overseas company incorporation, bank account opening, and tax advisory service.
TKEG Expat ™ (HK SAR) belongs to the TKEG Holdings Group

Please refer to "TKEG Holdings"'s website for more information.
請參閱「奕資控股」之網站獲取更多資訊。